Summary: Researchers have developed an innovative CAR T-cell therapy to combat glioblastoma, the most common malignant brain tumor in adults. This approach not only attacks tumor cells directly but also reprograms the tumor’s microenvironment, enabling immune cells to fight the cancer rather than protect it.
By injecting CAR T-cells directly into the tumor, scientists bypass barriers to immune response. Animal studies have shown promising results, and clinical trials will begin soon to evaluate this therapy in patients. This technique could offer a breakthrough for patients facing aggressive brain tumors. Researchers hope local injections of CAR T-cells may limit side effects on other parts of the body.
Key Facts:
- The new CAR T-cell therapy modifies the tumor environment to support immune attack.
- Injecting CAR T-cells directly into the tumor improves access and effectiveness.
- Animal studies showed complete elimination of cancer cells in implanted tumors.
Source: University of Basel
Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this aggressive tumor permanently disappear. The tumor cells are too varied, and the microenvironment is too tumor-friendly.
Researchers at the University of Basel and University Hospital Basel have now developed an immunotherapy that not only attacks the tumor—it also turns its microenvironment against it.
For some years now, CAR T-cells have been bringing new momentum to immunotherapies against cancer. How it works: experts take the patient’s T-cells and reprogram them in the lab so that they can recognize structures on cancer cells with the help of a receptor called chimeric antigen receptor (CAR).
Once back in the body, the T-cells hunt down and eradicate the cancer cells. This method has already been very successful in some forms of leukemia.
But solid tumors and especially brain tumors present obstacles to the success of CAR T-cells. First, it’s difficult for the cancer hunters to get inside a tumor. Second, not all the cancer cells necessarily have the structure the T-cells can recognize and attack. And third, solid tumors in human tissue have a microenvironment that fends off immune system attacks.
“Especially in the brain, where T-cells aren’t normally found, the environment is really hostile to them,” explains Professor Gregor Hutter of the University of Basel and the University Hospital Basel.
Tenacious tumors
Hutter and his team are searching for ways to fight glioblastoma. These brain tumors are unfortunately tenacious, usually returning even after operation and treatment. However, the time gained by an operation could be used to reprogram the patient’s own T-cells into CAR T-cells in the lab.
Injecting these directly into the regrowing tumor avoids the obstacle of the CAR T-cells not being able to get to the cancer. Once inside, the T-cells attack all cancer cells that carry the recognized structure.
From pro- to anti-tumor
The CAR T-cells developed by Hutter’s team have an extra feature aimed at altering the microenvironment. The researchers also give the therapeutic T-cells a blueprint for a molecule. This molecule blocks the signals the tumor uses to hijack the immune cells in its environment for its own purposes.
These signals allow the tumor to turn immune cells, or more precisely microglia and macrophages, into traitors to their own body. Instead of attacking the cancer, they prevent the immune system from attacking it.
Traitors turn back into defenders
Once the implanted molecule stops these tumor signals, macrophages and microglia can support the CAR T-cells in their attack on the glioblastoma— even on cancer cells that lack the specific recognized structure.
Trials with mice in whom the researchers implanted human glioblastoma cells have already shown that the treatment is very successful. The CAR T-cells were able to get rid of all of the cancer cells.
The research team also tested the method against lymphoma, which is cancer of the lymphatic system. The treatment also appeared promising in these tests.
Clinical studies to follow soon
As their next step, Hutter and his team want to offer the treatment to patients in a first clinical study to test its effectiveness and safety.
“Since we inject the treatment locally and don’t deliver it through the bloodstream, side effects on the rest of the body should be limited,” says Gregor Hutter.
However, possible side effects on the nervous system—which are already known to occur from other CAR T-cell therapies—and how much these can be curbed can only be determined through studies, he adds.
About this brain cancer research news
Author: Angelika Jacobs
Source: University of Basel
Contact: Angelika Jacobs – University of Basel
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Enhancing anti-1 EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker” by Gregor Hutter et al. Nature Communications
Abstract
Enhancing anti-1 EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker
A significant challenge for chimeric antigen receptor (CAR) T cell therapy against glioblastoma (GBM) is its immunosuppressive microenvironment, which is densely populated by protumoral glioma-associated microglia and macrophages (GAMs).
Myeloid immune checkpoint therapy targeting the CD47-signal regulatory protein alpha (SIRPα) axis induces GAM phagocytic function, but CD47 blockade monotherapy is associated with toxicity and low bioavailability in solid tumors.
In this work, we engineer a CAR T cell against epidermal growth factor receptor variant III (EGFRvIII), constitutively secreting a signal regulatory protein gamma-related protein (SGRP) with high affinity to CD47. Anti-EGFRvIII-SGRP CAR T cells eradicate orthotopic EGFRvIII-mosaic GBM in vivo, promoting GAM-mediated tumor cell phagocytosis.
In a subcutaneous CD19+ lymphoma mouse model, anti-CD19-SGRP CAR T cell therapy is superior to conventional anti-CD19 CAR T.
Thus, combination of CAR and SGRP eliminates bystander tumor cells in a manner that could overcome main mechanisms of CAR T cell therapy resistance, including immune suppression and antigen escape.
